Continue to site >
Trending ETFs
Guide

/

Health Care

/

Biotech & Pharma

/

Large Pharma

Large Pharma Dividends Stocks, ETFs, Funds

Overview

Payout

Div Growth

Returns

Buy Reco

Income Ratings

Upside Ratings

Filter by Security Type
As of 11/20/26

$1,347.11

-0.30%

$1.33 T

0.51%

$6.92

2/12

2027

$1.73

-

Estimated

29.45%

-

Johnson & JohnsonJohnson Johnson

JNJ | Stock | Common

$270.47

+1.25%

$670.92 B

1.98%

$5.36

11/24

2026

$1.34

-

Declared

33.89%

-

AbbVie Inc.AbbVie

ABBV | Stock | Common

$286.20

+0.94%

$517.59 B

2.54%

$7.28

1/15

2027

$1.82

-

Declared

28.92%

-

Merck & Co., Inc.Merck

MRK | Stock | Common

$133.72

+0.69%

$353.44 B

2.54%

$3.40

12/15

2026

$0.85

-

Estimated

28.80%

-

$150.47

-0.50%

$303.64 B

3.15%

$4.74

3/12

2027

$4.74

-

Estimated

16.00%

-

$152.00

-2.88%

$236.02 B

3.03%

$4.74

3/12

2027

-

-

Estimated

16.08%

-

$470.55

-1.60%

$230.49 B

2.61%

$12.41

3/26

2027

-

-

Estimated

11.55%

-

$471.42

-1.79%

$229.69 B

2.64%

$12.44

3/26

2027

-

-

Estimated

18.42%

-

PFIZER INCPFIZER

PFE | Stock | Common

$27.40

-0.51%

$162.27 B

6.28%

$1.72

1/22

2027

$0.43

-

Estimated

20.27%

-

$58.80

+0.79%

$125.40 B

4.29%

$2.52

1/01

2027

$0.63

-

Estimated

15.30%

-

SanofiSanofi

SNYNF | Stock |

$93.09

+0.11%

$123.10 B

5.20%

$4.84

5/13

2027

-

-

Estimated

3.86%

-

$37.76

-2.28%

$122.93 B

3.08%

$1.16

3/31

2027

-

-

Estimated

2.75%

-

Sanofi - ADRSanofi ADR

SNY | Stock | ADR

$46.52

+1.00%

$115.23 B

5.20%

$2.42

5/07

2027

$2.42

-

Estimated

2.66%

-

GSK PlcGSK

GLAXF | Stock |

$23.40

-4.29%

$106.41 B

0.00%

-

2/19

2027

-

-

Estimated

2.00%

-

GSK Plc - ADRGSK ADR

GSK | Stock | ADR

$47.76

-0.13%

$99.60 B

3.78%

$1.81

2/19

2027

$0.45

-

Estimated

2.60%

-

Eisai Co LtdEisai Ltd

ESALF | Stock |

$33.06

+1.47%

$13.16 B

3.03%

$1.00

3/31

2027

-

-

Declared

1343.49%

-

Get dividend stock picks, research and news in your inbox each week.

Our research team runs the industry’s toughest dividend screening test and only picks from the top 5%.